Cost-effectiveness analysis of abemaciclib and endocrine therapy combination for the adjuvant treatment of HR+/HER2-, node-positive, high-risk, early breast cancer

被引：2
|
作者：
Talwar, Ashna
Deshmukh, Ashish
Trivedi, Meghana
Aparasu, Rajender R.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-4364
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4364
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
    Johnston, Stephen R. D.
    Harbeck, Nadia
    Hegg, Roberto
    Toi, Masakazu
    Martin, Miguel
    Shao, Zhi Min
    Zhang, Qing Yuan
    Martinez Rodriguez, Jorge Luis
    Campone, Mario
    Hamilton, Erika
    Sohn, Joohyuk
    Guarneri, Valentina
    Okada, Morihito
    Boyle, Frances
    Neven, Patrick
    Cortes, Javier
    Huober, Jens
    Wardley, Andrew
    Tolaney, Sara M.
    Cicin, Irfan
    Smith, Ian C.
    Frenzel, Martin
    Headley, Desiree
    Wei, Ran
    San Antonio, Belen
    Hulstijn, Maarten
    Cox, Joanne
    O'Shaughnessy, Joyce
    Rastogi, Priya
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (34) : 3987 - 3998
  • [2] Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2-, node-positive, high-risk early breast cancer in Italy
    Davie, Alison
    Traore, Sory
    Giovannitti, Massimo
    Pompilio, Giuseppe
    Lambton, Mark
    Cakar, Esra
    Chatterjee, Anuja
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2023, 10 : 62 - 69
  • [3] Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: a plain language summary of the monarchE study
    D. Johnston, Stephen R.
    Rugo, Hope S.
    Tolaney, Sara M.
    Fernandez, Maria Munoz
    Wei, Ran
    Martin, Miguel
    FUTURE ONCOLOGY, 2024, 20 (28) : 2037 - 2048
  • [4] Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer
    Paluch-Shimon, Shani
    Neven, Patrick
    Huober, Jens
    Cicin, Irfan
    Goetz, Matthew P. P.
    Shimizu, Chikako
    Huang, Chiun-Sheng
    Lueck, Hans Joachim
    Beith, Jane
    Tokunaga, Eriko
    Contreras, Jessica Reyes
    de Sant'Ana, Rosane Oliveira
    Wei, Ran
    Shahir, Ashwin
    Nabinger, Sarah C. C.
    Forrester, Tammy
    Johnston, Stephen R. D.
    Harbeck, Nadia
    monarchE Investigators
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [5] Cost-effectiveness of abemaciclib plus endocrine therapy in high-risk HR+/HER2–early breast cancer in China
    Qiran Wei
    YuTing Xu
    Wei Liu
    Xin Guan
    Cost Effectiveness and Resource Allocation, 21
  • [6] Cost-effectiveness of abemaciclib plus endocrine therapy in high-risk HR+/HER2-early breast cancer in China
    Wei, Qiran
    Xu, Yuting
    Liu, Wei
    Guan, Xin
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)
  • [7] Patients' quality of life and side effect perceptions in monarchE, a study of abemaciclib plus endocrine therapy in adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer
    Tolaney, S.
    Blancas, I.
    Im, Y. -H.
    Rastogi, P.
    Brown, J.
    Shahir, A.
    Zimmermann, A.
    Boyle, F.
    BREAST, 2021, 56 : S20 - S21
  • [8] Efficacy and safety results by age in monarchE: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC).
    Hamilton, Erika P.
    Kim, Jee Hyun
    Eigeliene, Natalja
    Mavroudis, Dimitrios
    Median, Dragos Mircea
    Marconato, Heloisa
    Shevnia, Serhii
    Ozyilkan, Ozgur
    Puig, Juan Manuel
    Shannon, Catherine M.
    Munoz, Maria
    San Antonio, Belen
    Wei, Ran
    O'Shaughnessy, Joyce
    Johnston, Stephen R. D.
    Guarneri, Valentina
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC).
    Loi, Sherene
    Johnston, Stephen R. D.
    Arteaga, Carlos L.
    Graff, Stephanie L.
    Chandarlapaty, Sarat
    Goetz, Matthew P.
    Desmedt, Christine
    Sasano, Hironobu
    Liu, Deli
    Rodrik-Outmezguine, Vanessa
    Sireci, Anthony
    Sandoval, Cynthia
    Won, Helen H.
    Litchfield, Lacey M.
    Turner, Nicholas C.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA507 - LBA507
  • [10] Prognostic Utility of ctDNA Detection in The monarchE Trial of Adjuvant Abemaciclib Plus Endocrine therapy (ET) in HR+, HER2-, Node-positive, High-risk Early Breast Cancer (EBC)
    Loi, S.
    Johnston, S.
    Arteaga, C.
    Graff, S.
    Chandarlapaty, S.
    Goetz, M.
    Desmedt, C.
    Sasano, H.
    Liu, D.
    Rodrik-Outmezguine, V.
    Sireci, A.
    Sandoval, C.
    Won, H.
    Litchfield, L.
    Turner, N.
    BREAST, 2025, 80
12345